Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

ElixaMD vs Royal Medical Center

ElixaMD
Graded #251

Higher grade

vs+14.300000000000004
Royal Medical Center
Graded #492

Lower grade

The verdict

ElixaMD takes it — 63.7/100 to 49.4/100.

ElixaMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. ElixaMD is a doctor-guided online weight-loss telehealth offering compounded semaglutide injections from $179 the first month, with free shipping, no membership, no contract, and no insurance required.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueElixaMD +29
51
22
Dose & formulationElixaMD +10
52
42
Clinical oversightElixaMD +30
92
62
Labs & monitoringRoyal Medical Center +23
63
86
FulfillmentElixaMD +28
76
48
Contract termsRoyal Medical Center +10
45
55
ElixaMD · left barRoyal Medical Center · right bar

The numbers

MetricElixaMDRoyal Medical Center
WeighScore63.7/10049.4/100
GradeCC
Scorecard rank#251#492
Semaglutide$179/mo (starting dose, first-month rate, compounded)Not disclosed
TirzepatideNot disclosed$450/mo (2.5 mg dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
ElixaMD

Graded #251 · C

Strengths

  • Compounded semaglutide from $179 first month with free shipping, no membership, no contract, and no insurance required
  • Genuinely all-inclusive: 1:1 physician guidance, free dietician visits and care coaching, 24/7 support, and an all-in-one patient portal
  • Names its compounding pharmacies (RedRock Pharmacy, Beaker Pharmacy) — more transparent than most compounded sellers
  • HSA/FSA eligible; full legal suite (Terms, Privacy, Privacy Practices, Refund, Medical Consent, California Bill of Rights)

Where it loses points

  • $179 is a first-month/intro price — ongoing monthly cost is higher (tiers to ~$249-$299)
  • Compounded semaglutide is not FDA-approved (the site discloses this) — not brand Wegovy or Ozempic
  • Appears to offer compounded semaglutide only — tirzepatide is not advertised
  • Displays a generic LegitScript Certified badge but no verifiable seal/listing; state-availability list not published
Royal Medical Center

Graded #492 · C

Strengths

  • Physician founder Dr. Dagoberto Rodriguez, MD — Emory residency, former Coral Springs Medical Center chairman, U Miami faculty
  • Tirzepatide pricing fully itemized by dose tier ($450 / $650 / $800 / $1,100) — more transparent than 'starting at' floors
  • All-inclusive pricing bundles medication, supplies, injections, lab monitoring, and physician follow-ups
  • Broad catalog (HRT, TRT, peptides, ED, hair, vitamins) reflects an established multi-program clinic
  • Florida physician with 30+ years of practice — a strong physician-led care signal

Where it loses points

  • Operating legal entity not disclosed — only the 'Royal Medical Center' brand surfaced
  • Pharmacy partner not named — buyers can't verify licensure or 503A/503B status
  • No LegitScript badge displayed
  • States served not enumerated — site says 'nationwide' with no state list
  • Headline 'starting at $116/mo' conflicts with the actual $450/mo tirzepatide floor

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard